Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Merz, Maximilian [VerfasserIn]   i
 Seckinger, Anja [VerfasserIn]   i
 Hose, Dirk [VerfasserIn]   i
 Mai, Elias K. [VerfasserIn]   i
 Raab, Marc-Steffen [VerfasserIn]   i
 Goldschmidt, Hartmut [VerfasserIn]   i
 Jauch, Anna [VerfasserIn]   i
 Hillengaß, Jens [VerfasserIn]   i
Titel:Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma
Verf.angabe:Maximilian Merz, Thomas Hielscher, Anja Seckinger, Dirk Hose, Elias K. Mai, Marc S. Raab, Hartmut Goldschmidt, Anna Jauch, Jens Hillengass
E-Jahr:2016
Jahr:10 August 2016
Umfang:5 S.
Fussnoten:Gesehen am 28.08.2017
Titel Quelle:Enthalten in: American journal of hematology
Ort Quelle:New York, NY : Wiley-Liss, 1976
Jahr Quelle:2016
Band/Heft Quelle:91(2016), 11, Seite E473-E477
ISSN Quelle:1096-8652
Abstract:Deletion 17p13, del(17p), is associated with poor outcome in myeloma but some patients show long-term survival. With the current study we intended to identify factors impacting outcome of such high risk patients. We analyzed 110 newly diagnosed, symptomatic patients with del(17p) detected by fluorescence in situ hybridization (FISH) in CD138-purified myeloma cells to identify prognostic factors for survival. Age >65 years, ISS III, and elevated LDH negatively impacted survival. Patients with subclonal (10-60% of plasma cells) del(17p) had longer progression-free survival (PFS) than patients with del(17p) in >60% of plasma cells (26 vs. 19 months, P = 0.03). Additional gain of 1q21 was associated with shorter PFS (17 vs. 25 months, P = 0.01). Hyperdiploidy did not ameliorate impact of del(17p), but gain 19q13 predicted longer PFS (30 vs. 18 months, P = 0.01) and overall survival (50 vs. 29 months, P = 0.01). Multivariate analysis in transplant eligible patients (≤65 years) revealed better survival for patients treated with upfront autologous transplantation (hazard ratio, [95% confidence interval]: 0.15 [0.04, 0.58], P = 0.006). Application of maintenance therapy was associated with better survival in transplant-eligible patients (0.30 [0.09, 0.99], P = 0.05). We demonstrate heterogeneous outcome of patients with del(17p) according to baseline characteristics and treatment. 19q13 should be included in routine FISH panel, since gains were associated with better survival. Am. J. Hematol. 91:E473-E477, 2016. © 2016 Wiley Periodicals, Inc.
DOI:doi:10.1002/ajh.24533
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Volltext: http://dx.doi.org/10.1002/ajh.24533
 kostenfrei: Volltext: http://onlinelibrary.wiley.com/doi/10.1002/ajh.24533/abstract
 DOI: https://doi.org/10.1002/ajh.24533
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1562789643
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68154415   QR-Code
zum Seitenanfang